Mindfulness-Based Relapse Prevention in a Jail Drug Treatment Program.
Thomas Lyons1, Veronica Y Womack2, Wm Dustin Cantrell3
1a Illinois Circuit Court of Cook County , Chicago , Illinois , USA.
Substance Use & Misuse
|November 10, 2018
Summary
Mindfulness-Based Relapse Prevention (MBRP) is feasible in jail settings. This intervention, delivered by a culturally competent trainer, showed a significant increase in mindfulness among incarcerated men with substance use disorders.
Area of Science:
- Psychiatry
- Psychology
- Public Health
Background:
- Substance use disorders (SUDs) are prevalent in US correctional facilities, affecting over half of the incarcerated population.
- Mindfulness, characterized by present-moment awareness and nonjudgmental acceptance, is a key component of Mindfulness-Based Relapse Prevention (MBRP).
- Prior research indicates MBRP's efficacy in reducing substance use post-treatment.
Purpose of the Study:
- To adapt and evaluate the feasibility of MBRP within a jail-based SUD treatment program.
- To assess the impact of MBRP on mindfulness, anxiety, PTSD, and drug craving in incarcerated individuals.
Main Methods:
- A randomized controlled trial involving 189 incarcerated men in a jail SUD treatment program.
- Participants received either six weekly sessions of MBRP or a communication skills intervention (control).
- Pre- and post-intervention assessments measured mindfulness, anxiety, PTSD symptoms, and drug craving.
Main Results:
- Mindfulness was inversely correlated with anxiety, PTSD symptoms, and drug cravings at baseline.
- Both interventions led to significant reductions in anxiety, PTSD symptoms, and cravings, alongside increased mindfulness.
- The MBRP group demonstrated a statistically significant, albeit small, greater increase in mindfulness compared to the control group.
Conclusions:
- Mindfulness-Based Relapse Prevention is a feasible intervention within a jail setting.
- Culturally competent delivery of MBRP by trained facilitators is achievable in correctional environments.
- The findings support the potential of MBRP as a valuable tool for managing SUDs in incarcerated populations.
Related Concept Videos
Drugs for Treatment of Constipation-Predominant IBS
833
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
833
Drugs for Treatment of Ulcerative Colitis in IBD
519
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
519
Drugs for Treatment of Diarrhea-Predominant IBS
714
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
714
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
487
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
487
Cancer Prevention
8.1K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
8.1K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
538
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
538


